Imfinzi

AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
Pharmaceutical Business Review
AstraZeneca
Imfinzi
FDA
small cell lung cancer
orphan drugs
Flag link:
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
BioSpace
AstraZeneca
clinical trials
Imfinzi
extensive-stage small cell lung cancer
Calquence
CLL
Flag link:
AZ’s Imfinzi on target in small cell lung cancer, sets up Roche rivalry
AZ’s Imfinzi on target in small cell lung cancer, sets up Roche rivalry
Pharmaforum
AstraZeneca
Imfinzi
extensive-stage small cell lung cancer
Roche
Tecentriq
Flag link:
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Flag link:
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
Fierce Pharma
AstraZeneca
Imfinzi
lung cancer
NICE
UK
Flag link:
AZ begins liver cancer immunotherapy tie-up with AVEO
AZ begins liver cancer immunotherapy tie-up with AVEO
Pharmaforum
AstraZeneca
Aveo Oncology
cancer immunotherapy
Imfinzi
Fotivda
hepatocellular carcinoma
Flag link:
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fierce Pharma
AstraZeneca
Imfinzi
head and neck cancer
clinical trials
Flag link:
AstraZeneca Shows It Can Still Take Some Knocks
AstraZeneca Shows It Can Still Take Some Knocks
Yahoo/Bloomberg
AstraZeneca
Imfinzi
Flag link:
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
CP Wire
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Flag link:
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
AstraZeneca
Imfinzi
non-small cell lung cancer
Flag link:
Major Expected Events from AstraZeneca’s R&D in H2 2018
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
Flag link:
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Yahoo/Reuters
AstraZeneca
Pascal Soriot
cancer
Imfinzi
Flag link:
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
AstraZeneca
Japan
Imfinzi
Lynparza
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
CP Wire
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca
Imfinzi
non-small cell lung cancer
Flag link:
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Endpoints
FDA
Advair
AstraZeneca
Imfinzi
clinical trials
Flag link:
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
AstraZeneca
FDA
Imfinzi
non-small cell lung cancer
Flag link:
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
Endpoints
FDA
AstraZeneca
Imfinzi
lung cancer
Bavencio
Pfizer
Merck KGaA
Flag link:
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
BioPharma Dive
clinical trials
AstraZeneca
Mystic
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca plans new pivotal lung cancer trial with Incyte
AstraZeneca plans new pivotal lung cancer trial with Incyte
Yahoo/Reuters
AstraZeneca
Incyte
clinical trials
Imfinzi
epacadostat
lung cancer
Flag link:

Pages